THELMA

PHASE I MULTICENTER CLINICAL TRIAL EVALUATING THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN HER2-POSITIVE METASTATIC BREAST CANCER.

​

THE PRIMARY GOAL IS TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF THE COMBINATION OF T-DM1 AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN METASTATIC BREAST CANCER (MBC) PATIENTS PREVIOUSLY TREATED WITH TAXANES AND TRASTUZUMAB-BASED THERAPY.

​

IN ADDITION, PHARMACOKINETIC DATA ON THE COMBINATION OF T-DM1 AND LYPOSOMAL DOXORUBICIN WILL BE OBTAINED.

 

 

THELMA AT CLINICALTRIALS.GOV